Ascendis Pharma Completes Transition to Direct Nasdaq Listing for Ordinary Shares
ASND sits 62% above its 52-week low of $150.89.
Summary
Ascendis Pharma has completed its transition to a direct listing of ordinary shares on Nasdaq, replacing its previous ADS listing, effective April 20, 2026.
Key Events · Corporate Governance and Compliance · ASND
-
Direct Listing Commenced
As of April 20, 2026, Ascendis Pharma's ordinary shares began trading directly on The Nasdaq Global Select Market under the ticker symbol "ASND", replacing the American Depositary Shares (ADSs).
-
ADSs Exchanged
All outstanding ADSs were mandatorily exchanged for ordinary shares, with the last trading day for ADSs on Nasdaq being April 17, 2026. This finalizes the plan announced on April 8, 2026.
Analysis · ASND · Life Sciences
This filing confirms the successful execution of Ascendis Pharma's previously announced plan to transition its listing from American Depositary Shares (ADSs) to ordinary shares on The Nasdaq Global Select Market. This move simplifies the trading structure for investors and may enhance liquidity for the company's stock. The company is currently trading near its 52-week high, indicating strong investor sentiment as this structural change takes effect.
At the time of this filing, ASND was trading at $244.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15B. The 52-week trading range was $150.89 to $250.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.